Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax ; volume:118 ; number:4 ; day:15 ; month:8 ; year:2023 ; pages:526-528 ; date:10.2023
International journal of hematology ; 118, Heft 4 (15.8.2023), 526-528, 10.2023
- Urheber
-
Izutsu, Koji
Yamamoto, Kazuhito
Kato, Koji
Ishikawa, Takayuki
Fukuhara, Noriko
Terui, Yasuhito
Choi, Ilseung
Okubo, Sumiko
Ogawa, Natsumi
Sakai, Mizu
Nishimura, Yasuko
Chyla, Brenda
Sun, Yan
Maruyama, Dai
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12185-023-03646-3
- URN
-
urn:nbn:de:101:1-2023121314081667813140
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Izutsu, Koji
- Yamamoto, Kazuhito
- Kato, Koji
- Ishikawa, Takayuki
- Fukuhara, Noriko
- Terui, Yasuhito
- Choi, Ilseung
- Okubo, Sumiko
- Ogawa, Natsumi
- Sakai, Mizu
- Nishimura, Yasuko
- Chyla, Brenda
- Sun, Yan
- Maruyama, Dai
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia